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Abstract
The p97 AAA (ATPase associated with diverse cellular activities), also called VCP (valosin-
containing protein), is an important therapeutic target for cancer and neurodegenerative diseases.
p97 forms a hexamer composed of two AAA domains (D1 and D2) that form two stacked rings,
and an N-terminal domain that binds numerous cofactor proteins. The interplay between the three
domains in p97 is complex, and a deeper biochemical understanding is needed in order to design
selective p97 inhibitors as therapeutic agents. It is clear that the D2 ATPase domain hydrolyzes
ATP in vitro, but whether D1 contributes to ATPase activity is controversial. Here, we use Walker
A and B mutants to demonstrate that D1 is capable of hydrolyzing ATP, and show for the first
time that nucleotide binding in the D2 domain increases the catalytic efficiency (kcat/Km) of D1
ATP hydrolysis 280-fold, by increasing kcat 7-fold and decreasing Km about 40-fold. We further
show that an ND1 construct lacking D2 but including the linker between D1 and D2 is
catalytically active, resolving a conflict in the literature. Applying enzymatic observations to
small-molecule inhibitors, we show that four p97 inhibitors (DBeQ, ML240, ML241, and
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NMS-873) have differential responses to Walker A and B mutations, to disease-causing IBMPFD
mutations, and to the presence of the N-domain binding cofactor protein p47. These differential
effects provide the first evidence that p97 cofactors and disease mutations can alter p97 inhibitor
potency and suggest the possibility of developing context-dependent inhibitors of p97.
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Introduction
The highly conserved and abundant p97 protein belongs to the type II AAA ATPase enzyme
family and converts chemical energy from ATP hydrolysis into mechanical energy to unfold
proteins or disassemble protein complexes. p97 plays a critical role in cellular processes
such as Golgi membrane reassembly (1), membrane transport (2,3), degradation of proteins
by the ubiquitin–proteasome system (UPS) (4,5), regulation of myofibril assembly (6), cell
division (7), and protein aggregation (8–10). Because p97 functions in many protein
homeostatic regulatory processes, it is a potential therapeutic target for cancer and
neurodegenerative diseases (11–13).
Each monomer of p97 ATPase is composed of three domains (the N, D1 ATPase, and D2
ATPase domains) joined by linker regions. D1 and D2 each form a hexameric ring, which
stack to form a cylindrical structure, as revealed by X-ray crystallography (14,15). Although
it is clear that the D2 domain hydrolyzes ATP in vitro, the level of D1-specific ATPase
activity varies among different reports (16–18). Furthermore, genetic studies in yeast
reporting D1 ATPase activity as an essential function are controversial. For example, some
mutants that inhibit ATP hydrolysis in the D1 domain affect growth (17), whereas others do
not (19). However, a consistent observation is that the nucleotide-binding state of D1 is
tightly controlled (15,18). Thus, it is important to clarify the role of the D1 domain in vitro,
providing hypotheses that can then be tested in cells.
Adjacent to the D1 domain is the N domain, which functions as a protein-protein interaction
site that binds p97 cofactors (20,21). By recruiting cofactor proteins, the N domain links the
mechanochemical ATPase activity of p97 to many substrate proteins, accounting in part for
the broad range of cellular p97 functions. For example, cofactor p47 is required for p97-
mediated membrane fusion (22), by mediating binding of p97 to syntaxin 5 during the
reassembly of Golgi stacks at the end of mitosis (23). Binding of p47 to the N-terminus
alters the structure and function of p97 by significantly reducing the diameter of the p97 ring
(22) and inhibiting ATPase activity (24). Hence, p47 supports communication between the
N, D1 and D2 domains of p97.
There are several additional lines of evidence for conformational crosstalk among the three
domains of p97. Conformational changes occur during the ATPase cycle, including rotation
of the D1 and D2 rings with respect to each other, changes in the hexameric ring diameter,
and positioning of the N-domain (25–29). Additionally, pathogenic mutations in the N and
D1 domains alter nucleotide binding to the D1 domain and ATPase activity in the D2
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domain (29–31). Defining interactions between the D1 and D2 domains could provide
opportunities for developing small-molecule inhibitors with diverse mechanisms of
inhibition and perhaps diverse cellular effects.
In an effort to better understand the mechanistic and cellular functions of p97, a few potent
and specific small molecule inhibitors of p97 ATPase activity have been identified via high-
throughput screening, followed by chemical optimization (32–35). Published reversible p97
ATPase inhibitors fall into two classes – ATP-competitive (DBeQ, ML240, ML241) and
noncompetitive (NMS-873) inhibitors. NMS-873 is thought to inhibit p97 by binding at the
D1–D2 interdomain linker and stabilizing the D2-ADP-bound form, thus breaking the
catalytic cycle. Both competitive and noncompetitive inhibitors affect multiple p97-
dependent processes in cells, including ubiquitin fusion degradation (UFD), endoplasmic
reticulum associated degradation (ERAD), autophagy, and cancer cell growth. However,
investigations have not yet shown whether competitive compounds inhibit ATPase activity
arising from only D2 or from both D1 and D2, and whether inhibitors are influenced by
nucleotide binding states, disease mutations, or cofactor binding.
In this study, we enzymatically characterized a set of p97 constructs and mutations to
elucidate the effect of small-molecule p97 inhibitors on D1 and D2 domain ATPase
activities. We first clarified the in vitro activity of the D1 domain. We found that an ND1-
linker truncation is a robust, catalytically competent ATPase whose activity is similar to that
of the D1 domain in full-length p97. Interestingly, D1 showed ATPase activity in the full-
length protein only when the D2 domain was capable of binding nucleotides. Using our
enzymatically characterized set of p97 proteins, we addressed the domain specificity of four
potent p97 inhibitors on wild type (WT) p97. We then evaluated whether inhibition was
sensitive to pathogenic mutations in the ND1 domain or to the presence of bound p47, a p97
binding protein. DBeQ and NMS-873 inhibited both ATPase domains, whereas ML240 and
ML241 were specific for D2. In addition, inhibition of D2 by ML240 and ML241 was
altered by a pathogenic mutation in ND1 and upon p47 binding, indicating domain
communication within p97. Together, our results provide the framework for developing
domain, cofactor-complex, and pathway specific inhibitors (32), with the ultimate goal of
validating p97 as a potential therapeutic target.
Results
The Human p97 D1 Domain is a Competent ATPase
To resolve the controversy over whether the isolated D1 domain can hydrolyze ATP in vitro,
we prepared two truncated constructs: ND1 (residues 1–458) without the D1–D2 linker
region, and ND1L (1–480), which included the linker region (Fig. 1A). ND1 was used
previously to conclude that D1 was inactive (16), whereas ND1L has been used in
crystallography studies (31) and was recently reported to be catalytically active (29).
Specific activities with 600 µM ATP at room temperature for human and mouse p97 were
5.2±0.3 and 5.1±0.2 nmol Pi/min/nmol p97, respectively. We found that the ATPase activity
of ND1 was 1.4% of the WT level, whereas ND1L had 79% of the WT activity (at 600 uM
ATP; Fig. 1B). Thus, ND1L was 56-fold more active than ND1. As a comparison to ND1L,
we also prepared a truncation containing the D1–D2 linker region plus the D2 domain (LD2;
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amino acids 461–806). LD2 existed in dynamic multimer-monomer equilibrium (Figs. S1),
and thus it was not surprising that its ATPase activity was only 4% of WT values (Fig. 1B).
To address the difference in activities between ND1 and ND1L, we evaluated their
stabilities by differential scanning fluorimetry (DSF; Figs. 1C and D) and nucleotide binding
by surface plasmon resonance (SPR; Figs. 2A and B). Thermal stability studies showed that
addition of the linker strongly stabilized ND1 by 13 °C, to a temperature that approaches the
first melting transition of full-length p97. Additionally, ND1 showed multiple melting
transitions, whereas ND1L gave a single, highly cooperative melting curve. The increased
thermal stability and single-state melting curve suggested that ND1L formed a more stable
protein than ND1. To determine whether ND1 bound weakly to nucleotides, leading to low
catalytic activity, we monitored binding of nucleotides to ND1 and ND1L by SPR at 20 °C,
well below the melting temperature for ND1. Both ND1 and ND1L bound to ATP, ATPγS,
or ADP with similar binding affinities and kinetics (within 2-fold) (Fig. S2). Hence, the
linker region had only a small effect on nucleotide-binding affinity, which did not account
for the 56-fold increase in ATPase activity. Rather, we concluded that the linker region
rendered the D1 domain a competent ATP hydrolase mainly by substantially increasing its
thermal stability. We cannot rule out that the linker also favorably altered the
conformational dynamics of the protein.
By directly comparing the two constructs that were used in the previous studies, we
identified the source of the conflicting results on D1 activity. We demonstrated that ND1L
can hydrolyze ATP, which is in a good agreement with the recent report by Tang and
coworkers (29). In contrast, ND1 cannot hydrolyze ATP, which is consistent with the earlier
report by Song and coworkers (16).
Nucleotide Binding and Enzyme Kinetic Analysis of Walker A and B Mutants
We next directly compared the nucleotide binding affinities and activity of ND1L to full-
length WT p97 and active-site mutants. Walker A mutations (D1-K251A and D2-K524A)
disrupt ATP and ADP binding, whereas Walker B mutations (D1-E305Q and D2-E578Q)
disrupt activation of hydrolysis but allow ATP and ADP binding (16,17,36) (Fig. 1A). For
nucleotide binding analysis, full-length WT p97 and Walker A mutants were assayed by
SPR to compare the binding affinities of the D1 domain in the context of the full-length p97
protein versus isolated ND1 domains (Figs. 2C, S2, and Table S2). Nucleotides bound to
WT p97 with two distinct KD values. The tight binding affinity (132, 131, and 36.7 nM for
ADP, ATP, ATPgS, respectively) corresponded to the KD values obtained for ND1, ND1L,
and the D2-K524A mutant (which is unable to bind nucleotides in the D2 domain). Thus, the
D1 site bound to nucleotides with KD values in the 100 nM range. Based on these results and
the binding to the D1-K251A mutant (which is unable to bind nucleotides in the D1
domain), we ascribed the second, weaker binding affinity to the D2 domain (3.9, 5.5, and
1.1 µM for ADP, ATP, ATPgS, respectively). It is noteworthy that analysis of nucleotide
binding by SPR resulted in KD values similar to those obtained by fluorescence polarization
(see below) and tryptophan fluorescence (18,31), but gave ~10-fold tighter binding affinities
compared to values from ITC (18,31). Overall, our SPR results supported the previous
studies showing that D1 bound nucleotides more tightly than did D2 (18,35).
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We next measured the activity of the Walker A and B mutations, to evaluate how nucleotide
binding or ATP hydrolysis in one domain may alter the ATPase activity of the other
domain. We found that Walker A mutations lowered ATPase activity more than did the
Walker B mutations, supporting the importance of nucleotide binding in one domain for
ATPase activity of the other domain (Fig. 3A, black font indicates the active domain in each
protein). We included 0.01% Triton X-100 in our standard reaction buffer and observed a
1.7 fold increase in ATPase activity for WT p97 upon addition of Triton X-100 (Fig. 3A). In
general, the increase in ATPase activity by Triton X-100 was greater for the D1-active
Walker B mutant (D2-E578Q) compared to the D2-active Walker B mutant (D1-E305Q)
(Fig. 3A).
These activity data prompted us to measure steady-state kinetic constants (kcat, Km, and
kcat/Km), in order to understand the enzymology of D1 ATPase activity in the context of
full-length p97 and to evaluate the crosstalk between the D1 and D2 domains (Table S3 and
Figs. 3B and C). Published kinetic studies have focused on only full-length WT p97 (16) and
the full-length D1-E305Q mutant (37). Our data for these constructs were consistent with
the published values (16,38). The most striking deleterious effects of Walker mutations were
the 22-fold reduction in kcat (from 7.5 to 0.29 min−1) (Fig. 3D) and the10-fold reduction in
catalytic efficiency (kcat/Km; from 0.026 to 0.0013 min−1uM−1) (Fig. 3F) for the Walker A
mutation in the D2 domain (D2-K524A), compared to WT. Thus, the strongest effect on
catalysis came from blocking binding of nucleotides to the D2 domain. Simply blocking
catalysis of D2 without blocking nucleotide binding (D2-E578Q) gave a modest 3-fold
effect on kcat and actually increased catalytic efficiency through a reduction in Km (kcat/Km
from 0.026 to 0.39 min−1uM−1). D1-E305Q also showed a slightly higher kcat/Km than WT.
Taken with D2-E578Q, the data suggested a cross-inhibitory effect on the activity of the D1
and D2 domains. These observations were consistent with the negative cooperativity
between the D1 and D2 rings shown for mouse p97 (28) and with the recent demonstration
that the presence of D2 inhibited D1 activity (29). Finally, it is noteworthy that ND1L gave
the same kinetic constants as D2-E578Q (Table S3 and Fig. 3C). Thus, ND1L can serve as
an accurate kinetic model of the D1 domain in the full-length p97.
It is noteworthy that adding detergent (Triton X-100) to the assay buffer was critical for
observing robust ND1L activity (Fig. 3C). Triton X-100 increased kcat 4.7-fold, and had no
effect on Km. This result suggested that detergent facilitated catalysis, perhaps by aiding the
release of prebound ADP from the hexamer (18,29). It was also likely that detergent
prevented protein aggregation and reduced protein binding to the surface of the plastic assay
plates. We have included 0.01% Triton X-100 in our standard reaction buffer (32,34) and
detergents like Triton X-100 and Tween-20 are frequently added when testing
smallmolecule inhibitors to prevent compounds from forming colloids that can cause non-
specific enzyme inhibition (39).
ATP-Competitive p97 Inhibitors, ML240 and ML241 are Selective for the D2 domain
We previously identified three potent, ATP-competitive p97 inhibitors (DBeQ, ML240, and
ML241; Fig. 4A) (32,34). Nerviano Medical Sciences and Genentech, Inc., identified
NMS-873 as a potent non-ATP-competitive p97 inhibitor, with potencies in the low
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nanomolar range (Table S4) (33,35). To investigate whether these four p97 compounds
inhibit the ATPase activity of D1, D2, or both domains, IC50 values were determined for
WT p97 and five variants in the presence of 200 µM or 875 µM ATP. Lower potencies were
observed for inhibition of WT p97 (roughly 2 to 5-fold increases in IC50; Fig. 4 and Tables
S4 and S5).
The ATP competitive inhibitors were sensitive to Walker A and B mutations in both
domains. There was a 2.7- to 10-fold increase in IC50 for D1-E305Q (Walker B mutant in
the D1 domain) for DBeQ, ML240, and ML241 (Figs. 4 B–D). These increases in IC50 can
be partly explained by the 2.4-fold decrease in Km for D1-E305Q, because ATP competitive
inhibitors are sensitive to the levels of ATP binding (Fig. 3E). In contrast to the smaller
effects found for the D1 D1-E305Q mutant, ML240 was inactive toward D2 mutants D2-
E578Q and D2-K524A, and toward ND1L. ML241 was also inactive towards D2-K524A
and ND1L, and showed 147-fold weaker inhibition for D2-E578Q. Thus, both ML240 and
ML241 were D2 selective inhibitors (Figs. 4 C and D). DBeQ was less selective, showing 8
to 10-fold weaker inhibition of D2-E578Q, D2-K524A, and ND1L (Fig. 4B). The “D2
specific” inhibitors were nevertheless sensitive to changes in D1. For example, the D1 D1-
K251A mutation increased the IC50 for ML240 and ML241 by 27-fold with 200 µM ATP
and ML240 can not inhibit D1 D1-K251A with 875 µM ATP, suggesting that the
architecture of the D2 active site was changed significantly due to the mutation and/or due to
the absence of nucleotide binding to D1. This result was consistent with our kinetic analysis
of D1-K251A (Fig. 3B), which also showed strong effects of this mutation on the activity of
the D2 domain.
The allosteric inhibitor NMS-873 sensed mutations in the D2 domain, but was insensitive to
D1 mutations (Tables S4 and S5, Fig. 4E). In agreement with the published data for Walker
A mutants, NMS-873 inhibited D1-K251A and WT p97 similarly, but could not bind and
inhibit D2-K524A (35). Unexpectedly, NMS-873 inhibited D2-E578Q (IC50 1.0 µM, or 25-
fold higher than for WT p97, Fig. 4E), suggesting that maintaining D2 in the ATP-bound
state allowed NMS-873 to bind and prevent D1 from hydrolyzing ATP. In addition to the
proposed mechanism, whereby NMS-873 prevented ADP release from D2, our D2-E578Q
data suggested that NMS-873 locked p97 into a conformation that may have also prevented
ADP release from D1. The ATP-binding sites in D1 and D2 are similar for DBeQ binding,
because the IC50 values for D1-E305Q, D1-K251A, D2-E578Q, D2-K524A, and the
isolated ND1L are almost identical at higher concentrations of ATP (Table S5). Therefore,
DBeQ inhibits both D1 and D2 ATPase activities similarly. However, ML240 and ML241
behave quite differently. They are much more sensitive to Walker A and B mutations and
cannot inhibit D2-E578Q, D2-K524A, and ND1L as potently as seen for D1-E305Q. Thus,
they are more selective for inhibiting D2 ATPase activity. Even though NMS-873 does not
bind to ATP binding sties, its ability to bind to p97 and inhibit D1 ATPase is diminished for
the D2-K524A mutant (35). However, when D1 and D2 can both bind nucleotides (as in D2-
E578Q), NMS-873 inhibits D1 ATP hydrolysis, but 25-fold less potent as compared to D1-
E305Q p97. In summary, the four inhibitors fall into three classes: NMS-873, which binds at
the D1-D2 interface, seems to inhibit ATPase activity from both D1 and D2 domains; the
ATP-competitive inhibitors DBeQ can inhibit both D1 and D2 ATPase activity; and ML240
and ML241 are selective against the D2 domain.
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Taken together, the D1 ATPase activity is more difficult to block by p97 inhibitors (Figs. 4
B to E, D2-E578Q). This is consistent with results of our steady state kinetic analysis of D2-
E578Q, the mutant with the lowest Km for ATP (Figs. 3B, C, and E) and tighter nucleotide
binding to D1 (Table S2 and Figs. 2 and 5A). Furthermore, all ATP-competitive inhibitors
(DBeQ, ML240, and ML241) displayed lower inhibitory potencies (higher IC50 values)
toward all ATPase-defective mutants (Walker A/B mutants), compared to the WT. On the
other hand, the non-ATP-competitive inhibitor NMS-873 showed similar potencies toward
the D1 mutants (D1-E305Q and D1-K251A), compared to the WT, but much lower
potencies toward D2 mutants (D2-E578Q and D2-K524A). In other words, the mutants in
general are more resistant to inhibitors, especially the D2 Walker A mutant (D2-K524A).
Such resistance seems expected, due to the significant impairment of their steady state
behavior toward ATP.
To determine if D2 domain-selective inhibitors affect ATP binding to the D1 domain, we
performed experiments with fluorescent BODIPY-FL-ATP. Fluorescence anisotropy was
detected when BODIPY-FL-ATP bound to WT p97 (Fig. 5A, red line). The KD values for
BODIPY-FL-ATP binding were similar for WT p97 and the Walker A mutation in the D2
domain (D2-K524A, Fig. 5A, blue line), indicating that nucleotide binding monitored in WT
p97 was predominantly to D1. As anticipated by SPR data, BODIPY-FL-ATP does bind to
D2 (D1-K251A, Figure 5A, black line) with a ~23-fold weaker affinity than for D1. These
results are also consistent with the binding of other fluorescent probes to WT p97 and
Walker A mutants (18,35). We then carried out binding experiments in the presence of 50
µM ML240 and ML241 and demonstrated that inhibiting D2 with ML240 and ML241 did
not affect BODIPY-FL-ATP binding to D1 (Fig. 5B).
IBMPFD/ALS Mutations and p47 Cofactor Binding Affect Potency of the D2-selective p97
Inhibitors
Mutations at the ND1 interface of p97 cause IBMPFD/ALS (40,41), a devastating
degenerative disorder that has no known treatment. Therefore, p97 inhibitors that can correct
the increased ATPase activity of mutants to WT levels might be useful for exploration in
animal models, as a possible starting point for research on treatment approaches.
To begin to investigate this opportunity, we prepared a series of IBMPFD p97 mutants and
tested the activity of ML240 and ML241. We first confirmed a prior report (38) that the
elevated ATPase activity from mutants such as A232E arose from turnover in D2 (Fig. 6A).
As expected, when D1 activity was knocked out by D1-E305Q, D2 activity was increased
by A232E, whereas A232E had no affect on D1-mediated ATPase activity (D2-E578Q). We
then determined IC50 values for the D2-selective inhibitors, ML240 and ML241, against
eight mutants that cause disease (Fig. 6B). Interestingly, some mutants were less sensitive to
the inhibitors. For example, the IC50 value for ML240 was 5-fold higher for the R95G
mutant, compared to WT p97. This result demonstrated that the conformation at the ND1
interface altered binding of inhibitors to the D2 ATP site. Our data suggest that it may be
possible to develop a mutant selective inhibitor. Selective inhibition of the mutant subunit
may reduce the pool of active p97 mutants (or hexamers containing mutants) within cells, so
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that cells use predominantly WT hexamers. However, additional work will be required to
develop mutant-selective inhibitors.
Inhibitor potency was clearly affected by IBMPFD/ALS mutations and by the nucleotide
binding state of the D1 domain of p97, even though these mutations are distal to the small-
molecule binding site in the D2 domain. By extension, we hypothesized that cofactor
binding to p97 might also be critical for p97 inhibitor potency. Therefore, we evaluated
inhibitor potency for p97–p47 complexes at four concentrations of p47 (Table S6 and Fig.
7). All concentrations of p47 increased the IC50 of DBeQ 4- to 6-fold (Fig. 7A). More
dramatically, p47 trimer concentrations greater than 16.7 nM increased IC50 values of
ML240 and ML241 more than 49-fold and 37-fold, respectively (Figs. 7B and C). In
contrast, only a minor 2-fold effect was detected for the allosteric inhibitor NMS-873 (Fig.
7D). This result provided the first demonstration that a major p97 cofactor, p47, can
influence the potency of ATP-competitive p97 inhibitors.
Discussion
Our interest is to understand the function of the D1 and D2 p97 ATPase domains, through
kinetic analysis of mutants, and use of small molecule inhibitors. The impetus to evaluate
effects of p97 inhibitors came from work on the D1 inhibitor, Eeyarestatin I (27), and the N-
domain inhibitor, Xanthohumo1 (28). Neither of these compounds blocks full-length p97
ATPase activity, but they inhibit some p97-dependent cellular activities. The results suggest
that modifying activity of either the N or D1 domain by small molecules may alter different
p97 functions in cells. Moreover, the human disorder known as IBMPFD/ALS is associated
with dominantly inherited, missense mutations in the N, ND1 linker, and D1 domains (that
cause high p97 ATPase activity), but not by mutations in D2 (29,30).
The AAA ATPase p97 is a dynamic molecular machine that consists of two ATPase
domains, D1 and D2, which function to drive the molecular remodeling of protein
substrates. We first did a systematic comparison of D1 and D2 ATPase activity to resolve
the controversy on whether D1 is an active ATPase. With the active ND1L mutant and
Walker A and B mutants for both D1 and D2, we carried out steady-state kinetic analyses
and dose-dependent titrations with 4 p97 inhibitors against these mutants.
Our steady-state kinetic analyses provide molecular insights into the roles of both ATPase
domains, and also indicate that nucleotide binding and p97 inhibitors modulate each domain
interdependently. We show that the ND1L domain is a catalytically competent ATPase,
resolving a debate in the literature. Tang and coworkers (29) demonstrated ATPase activity
in an ND1L construct (Fig. 1A), whereas two other labs published that ND1 was inactive
(16,18). Moreover, our results provide a plausible explanation for the conflicting reports on
whether D1 is an active ATPase. We show that the D1–D2 linker region (residues 459–480)
dramatically improves thermal stability (Fig. 1D). However, both ND1 and ND1L are
capable of binding nucleotides when the temperature is below the melting temperature (Figs.
2A and B). These data are consistent with X-ray crystallography studies that reveal identical
active-site structural arrangements for ND1, ND1L, and the ND1 domain in the full-length
enzyme (14,15,31,42). One possible explanation for the 56-fold increase in activity in the
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ND1L construct is that the linker region positions a water molecule into a catalytically
competent orientation to hydrolyze ATP.
In this study, we provide quantitative analysis of kinetic constants for the D1 and D2
ATPase domains of human p97, by using point mutations at the conserved Walker A and B
positions of D1 and D2 (16,17,36) and an isolated ND1L domain. Additionally, we examine
the binding kinetics and dissociation constants for Walker A mutations and isolated ND1
domains. Our estimated Km of 287 µM for ATP at room temperature for human p97 is
within the range of published values. Specifically, estimated Km values for p97 isolated
from rat liver are 550 µM or 620 µM (24,43) for ATP at 37 °C. Three studies found Km
values of 330 µM (16), 360 µM (38), or 49 µM (44) for recombinant mouse p97 purified
from E. coli. The Km for the C. elegans p97 homolog is 390 µM (37). Some variation among
different reports may be due to differences in assay methods.
Our results showed that ATP hydrolysis within the D1 domain of a full-length p97 protein
containing a Walker B mutation in D2 (D2-E578Q) exhibited Michaelis-Menten behavior
almost identical to that for ND1L (Fig. 3C, Table S3). Consistent with the enzymology,
isolated ND1L was found to bind nucleotides with similar affinities as the D1 domain in
full-length p97 (Figs. 2 and S2). Furthermore, the Km of D1 (D2-E578Q) for ATP was ~20-
fold less than the D2 value (D1-E305Q) (Fig. 3E), consistent with the 10-fold tighter
nucleotide binding to D1 than to D2 (Table S2) (18). Although the D1 maximal velocity was
about 3.5 times lower than for WT p97 (Figs. 3C and D), the kcat/Km for D1 is actually 14-
fold higher than the WT value, indicating that D1 is a catalytically competent ATPase within
full-length p97.
Previous studies hinted that intra- and inter-domain communication within the p97 hexamer
is important for p97 activity (17,27–29,37). We found that preventing nucleotide binding in
the D2 domain using a Walker A mutant (D2-K524A) drastically impaired both the D1 Km
for ATP (~40-fold weaker) and catalytic activity (7-fold lower kcat), as compared to a D2-
E578Q mutant (Fig. 3A). This striking finding indicates that nucleotide binding to D2 is
required for D1 activity in full-length p97. Hence, domain communication within the p97
hexamer critically controls the capacity of both domains to hydrolyze ATP. Moreover, the
tighter Km for D1 may imply that D1 ATPase activity is more important under stress
conditions, when cellular ATP concentration is depleted (45–48).
In contrast to our experiments with ND1L, a truncation strategy was not suitable for
investigating the catalytic efficiency of the D2 ATPase, because isolated D2 cannot form
stable hexamers (Fig. S1) (49), Instead, we focused on D2 ATP hydrolysis within the full-
length p97 protein. The Walker B mutation at D1 (D1-E305Q) resulted in a 2.4-fold
decrease in Km for the D2 domain, which increased its catalytic efficiency (kcat/Km) by ~ 3-
fold (Table S3). Conversely, the Walker A mutation in D1 (D1-K251A) prevented D2 from
reaching maximal WT activity, no matter how much ATP was present. Because the Km
values are similar for D1-D1-K251A and D1-E305Q (Figs. 3A and D), we conclude that
nucleotide binding to D1 is essential to achieve maximal kcat values for D2 (18,37).
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Together, our results support the presence of domain communication within the full-length
WT p97 ATPase, in which nucleotide binding to one ATPase domain is essential for activity
of the other domain. Further work is needed to decipher the precise roles and the molecular
mechanisms of this communication. In particular, the importance of D1 ATPase activity in
cells is controversial (17,19,29), and our enzymatic studies with mutants pave the way to
investigate the cellular role of D1 activity, cooperativity between D1 and D2, and the extent
to which p97 cofactors are involved in regulating such communication.
Our results also have implications for the design of p97 inhibitors for use in cancer and
neurodegeneration. We have generated a set of tools to develop D1- and D2-domain specific
inhibitors, and clearly demonstrated the existence of two types of ATP-competitive
inhibitors. DBeQ inhibits both D1 and D2, whereas ML240 and ML241 only inhibit the D2
ATPase domain (Figs. 4 A–C and Tables S4 and S5). Moreover, inhibition by ML240 and
ML241 is sensitive to IBMPFD/ALS mutations in p97 (Fig. 6B), suggesting that IBMPFD/
ALS-selective inhibitors might be developed via either structure-based drug design or high-
throughput screens.
Another significant finding in this study is the roughly 50-fold decrease in ML240 potency
in the presence of p47, providing the first evidence that p97 cofactors can affect the potency
of ATP-competitive inhibitors (Figs. 7A–C, and Table S6). These results favor an
interpretation that the p97–p47 complex exists in a conformation that cannot be inhibited by
ML240 and ML241 as effectively as by the allosteric inhibitor NMS-873. Indirect evidence
suggests that p97 ATP binding sites exist in different conformations in the presence of p47,
because p47 dramatically changes the global p97 conformation (21,22,50) and lowers the
maximal velocity of ATPase activity by 5-fold (24). Thus, it may be possible to develop
complex-specific p97 inhibitors for p47 and other p97 cofactor proteins (51). It is enticing to
consider whether ML240 and ML241 may inhibit a subset of p97 complexes in cells,
whereas NMS-873 may be a broad-spectrum inhibitor. Future in vivo studies are needed to
compare anti-cancer potencies and general toxicities of distinct classes of p97 inhibitors.
Taken together, our results provide a new way to consider domain communication in p97
and the tools to develop D1- or D2-domain selective, complex-specific, and disease-mutant-
selective p97 inhibitors.
Materials and Methods
Materials
Plasmids used are listed in Supplemental Table S1.
BIOMOL Green ATPase Assay
Purified p97 (25 µL of 50 µM; final concentration in the reaction was 25 nM) was diluted in
40 mL of assay buffer [10 mL of 5× assay buffer A (1× = 50 mM Tris pH 7.4, 20 mM
MgCl2, 1 mM EDTA,) mixed with 30 mL water and 50 µL 0.5M TCEP, 50 µL 10% Triton]
to make the enzyme solution. Some experiments represented in Figures 3A and 3C were
performed without 0.01% Triton X-100. In these experiments, 50 µL 10% Triton was not
added to the assay buffer. For all other experiments, 50 µL 10% Triton was included. 40 µL
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of enzyme solution was dispensed into each well of a 96 well plate. The WT p97 ATPase
assay was carried out by adding 10 µL of 1000 µM or 4375 µM ATP (Roche, pH 7.5) to
each well and incubating the reaction at room temperature for 35 or 15 min, respectively
Reactions were stopped by adding 50 µL of BIOMOL Green reagent (Enzo Life Sciences).
Absorbance at 635 nm was measured after 4 min on the Synergy Neo Microplate Reader
(BioTek). To determine the steady-state kinetic constant, eight final ATP concentrations
were used (62.5, 125, 250, 375, 500, 625, 750, 875 µM) or (3.9, 7.8, 15.6, 23.4, 31.25, 62.5,
93.8, 125 µM). For mutants, reaction times were adjusted according to specific activities, to
give acceptable absorbance readings. Michaelis-Menten constants were calculated from
eight replicates by fitting data to Equation 1 using GraphPad Prism 6.0.
(1)
where ν is the initial velocity, kcat is the turnover number, [E]t is the total enzyme
concentration, [S] is the substrate concentration, and Km is the concentration of substrate to
reach half maximal velocity.
ATPase Assay for Determining IC50 Values of Inhibitors
Purified p97 (25 µL of a 50 µM stock solution) was diluted in 30 mL of assay buffer [10 mL
of 5×assay buffer A (1×= 50 mM Tris pH 7.4, 20 mM MgCl2, 1 mM EDTA,) mixed with 20
mL of water, 50 µL of 0.5M TCEP, and 50 µL of 10% Triton X-100] to make the enzyme
solution. 30 µL of enzyme solution was dispensed into each well of a 96 well plate. The test
compound (10 µL) or DMSO (12%, 10 µL) was then added to each well, and the plate was
incubated at room temperature for 10 min. The reaction was initiated by adding 10 µL of 1
mM ATP (pH 7.5) to each well at room temperature. After 30 min, the reaction was stopped
by adding 50 µL of BIOMOL Green reagent. Absorbance at 635 nm was measured after 4
min. DBeQ was assayed at a range of concentrations (0, 0.04, 0.12, 0.37, 1.1, 3.3, 10, 30
µM). The other compounds were assayed at (0, 0.013, 0.04, 0.12, 0.37, 1.1, 3.3, and 10 µM).
IC50 values were calculated from four replicates by non-linear regression analysis with
Equation 2 using GraphPad Prism 6.0.
(2)
where X is the compound concentration.
Surface Plasmon Resonance (SPR)
The kinetic parameters for the direct binding of nucleotides to p97 were measured on a
Biacore 4000 instrument. Neutravidin-coated sensor chips were prepared on CM5 chips, as
follows: the surface was activated by injecting a 1:1 mixture of 60 mM N-
hydroxysuccinimide and 240 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide for 7
min, followed by a 7 min injection of 0.25 mg/mL NeutrAvidin (Thermo Scientific) in 10
mM acetic acid pH 4.5. The surface was then blocked by a 2 min injection of 1 M
ethanolamine, pH 8.3.
p97 proteins containing site-specific biotinylation (AviTag; Avidity) were expressed and
purified from E. coli (see Supplemental materials). Purified protein was immobilized in 10
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mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 0.05% Tween 20. Protein was
immobilized to 4000–6000 resonance units (RUs) by injecting 100–500 µg/mL of protein
for 1 min at 25 °C. Protein immobilization was followed by a 2 min injection of 0.2 mg/mL
amino-PEG-biotin (Thermo Scientific) to block any remaining biotin binding sites. A
reference surface was created using the same protocol with omission of the protein injection
step.
Binding of ADP (Sigma A2754), ATP (promega V703A) and ATP' S (Sigma A1388) were
measured in duplicate in SPR running buffer (25 mM Tris pH 7.5, 150 mM NaCl, 10 mM
MgCl2, 0.5 mM TCEP, 0.05% Tween 20) at 20 °C. Nucleotides were injected at a flow rate
of 30 µL/min for 90–180 seconds, with a dissociation time of 180–600 seconds.
SPR experiments were carried out in the presence of 0.05% Tween-20, whereas the
BIOMOL Green ATPase assays were carried out in the presence of 0.01% Triton X-100.
Because Tween-20 and the BIOMOL Green reagent are incompatible, to compare the
ATPase activities of WT p97 in the presence of Triton X-100 and Tween-20, we used the
ADP-Glo assay. Similar to the BIOMOL green assay, we found the addition of 0.01% Triton
X-100 or Tween-20 modestly increased WT p97 activity by 1.79- and 1.97-fold,
respectively. The addition of 0.05% Tween-20 further increased the activity by 2.8-fold over
no detergent conditions.
Differential Scanning Fluorimetry (DSF)
The thermal stabilities of p97 ND1 and ND1L domains were measured on a Mx3005P q-
PCR (Stratagene) instrument in a 24-well Thermo-Fast PCR plate (Thermo Scientific). Four
replicates of 20 µL of ND1, ND1L or full-length p97 (2.0 µM) were mixed with 5 µL of a
1:200 dilution of SYPRO Orange Protein Gel Stain (Sigma) in 25 mM Tris, pH 7.5, 150 mM
NaCl, 10 mM MgCl2, 0.5 mM TCEP. Samples were heated from 25 °C to 100 °C at 1 °C/
min, and fluorescence (Ex = 492 nM, Em = 610 nM) was measured every minute. Curves
were normalized, and the melting temperature was calculated from the first derivative using
the FIT for DSF website (skuld.bmsc.washington.edu/FIT/).
Fluorescence Anisotropy
Fluorescence anisotropy experiments were completed in black, low volume, non-binding
384-well plates (Corning) in 25 mM Tris, pH 7.5, with 150 mM NaCl, 10 mM MgCl2, and
0.5 mM TCEP, by mixing 10 µL of protein (200 µM – 48 pM; 2-fold dilutions) with 10 µL
of BODIPY-FL-ATP ligand (Life Technologies; 20 nM). After a 30-minute incubation,
fluorescence polarization was measured on an Analyst HT plate reader (Molecular Devices)
using 485 nm and 530 nm excitation and emission filters, respectively. No time-dependent
change in anisotropy was observed over 30 minutes (e.g., due to catalytic turnover of the
BODIPY-FL-ATP probe). Background fluorescence (protein only) was subtracted from the
parallel and perpendicular intensities before calculating anisotropy. The KD of BODIPY-FL-
ATP was determined with GraphPad Prism 5.0, by Equations 3 and 4 to account for ligand
depletion:
(3)
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(4)
where [RL] is the concentration of the p97-BODIPY-FL-ATP complex, [L] is the
concentration of BIODPYFL- ADP, [R] is the concentration of p97, A is anisotropy, Af is
the anisotropy of BODIPY-FL ATP, and Ab is the anisotropy of the p97-BODIPY-FL-ATP
complex.
To determine if DBeQ, ML240, or ML241 altered nucleotide binding to the D1 domain of
p97, 5 µL of WT p97 (100 µM – 24 pM; 2-fold dilutions) was mixed with 5 µL of 5%
DMSO or compound (200 µM in 5% DMSO buffer) and 10 µL of 20 nM BODIPY-FL-ATP.
Materials and additional methods, including procedures for protein expression, are available
in supplemental data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
Potent p97 inhibitors are developed, but whether they inhibit D1 activity is unknown.
Inhibitors can differentially target D1, D2, and p97-cofactor complexes.
This represents a step toward domain- and complex-selective p97inhibitors.
ML240 and ML241 are D2-selective inhibitors and p47 influences their potency.
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Figure 1. Comparison of WT and isolated domain variants
(A) Human p97 mutants and variants generated in this study. (B) ATPase activities of WT
p97, ND1, ND1L, and LD2 domains with 0.01% Triton X-100 at 600 µM ATP. (C, D) The
linker region (a.a. 459–480; SNPSALRETVVEVPQVTWEDIG) stabilized the D1 domain.
Differential scanning fluorimetry revealed enhanced stability of the ND1 domain with the
linker peptide (i.e., a 13 °C higher melting temperature). Melting temperatures: ND1 (Tm
41.9 °C, 55.7 °C), ND1L (Tm 55.5 °C) and full-length p97 (Tm 59.7 °C, 66.0 °C).
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Figure 2. Analysis of nucleotide binding to p97
(A, B) SPR sensorgrams for ADP (0–16.67 µM, 3-fold dilutions) binding to the ND1 (A)
and ND1L (B) domains of p97. Response data were fit to a one-site kinetic model (orange
lines) to obtain kinetic binding parameters. (C) SPR sensorgrams for ADP (0–150 µM, 3-
fold dilutions), binding to full-length p97. Data were fit to a two-site kinetic binding model
to obtain KD values for the two ATPase domains in p97.
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Figure 3. Steady state kinetic analyses of human p97 ATPase activity
(A) ATPase activities of WT and Walker A and B mutants for D1 (D1-K251A; D1-E305Q)
and D2 (D2-K524A; D2-E578Q), with or without 0.01% Triton X-100 at 200 µM ATP. Blue
lettering indicates the ATPase active domain in each protein. Red lettering indicates the
Walker A mutant. Green lettering indicates the Walker B mutant. (B) and (C) Michaelis-
Menten plots of ATP hydrolysis for WT and mutant p97. From (D) to (F), black font
indicates the ATPase active domain in each protein. (D) WT p97 hydrolyzes 7.48 ± 0.01
ATP molecules per minute per monomer (turnover number, kcat, min−1). The Walker A
mutation of D2 (D2-K524A) decreases kcat 22-fold. (E) The apparent Michaelis-Menten
constant, Km, of WT p97 is 287 ± 10 µM. The Walker B mutation of D2 (D2-E578Q)
decreases Km 50-fold. (F) The catalytic efficiency (kcat/Km) for WT p97 is 0.026 min−1
µM−1. A 2-fold decrease for the Walker A mutation of D1 (D1-K251A), a 3-fold increase
for the Walker B mutation of D1 (D1-E305Q), a 15-fold decrease for the Walker A mutation
of D2 (D2-K524A), and a 14-fold increase for the Walker B mutation of D2 (D2-E578Q)
together suggest that D1 is a catalytically competent ATPase, when D2 is able to bind to
nucleotides.
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Figure 4. ML240 and ML241 selectively inhibit the D2 domain
(A) Structures of DBeQ, ML240, ML241, and NMS-873. (B) to (E) IC50 (µM) of WT, D1-
E305Q, D1-K251A, D2-E578Q, D2-K524A, and ND1L for (B) DBeQ, (C) ML240, (D)
ML241, and (E) NMS-873 with 200 µM ATP or 875 µM ATP.
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Figure 5. Binding of D2 selective inhibitors does not alter ATP binding to the D1 domain
(A) Fluorescence anisotropy measurements for BODIPY-FL-ATP binding to WT p97 and
Walker A mutants. (B) Binding of the BODIPY-FL-ATP probe in the presence of the D2
specific inhibitors, ML240 and ML241. Data were determined in triplicate, and errors in
binding affinities shown are standard errors of the mean of the fit.
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Figure 6. IBMPFD/ALS p97 mutations affect potency of ML240 and ML241
(A) ATPase activities of WT p97 and the A232E disease mutant (with Walker B mutations)
indicated that the elevated ATPase activity originated from D2. (B) Inhibition of ATPase
activity of WT p97 and eight disease mutants by ML240 and ML241.
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Figure 7. A Major p97 cofactor, p47, decreased potency of ML240 and ML241
IC50 values (µM) for p97 inhibitors against p97-p47 mixtures for (A) DBeQ, (B) ML240,
(C) ML241, and (D) NMS-873.
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